H.C. Wainwright assumed coverage of Can-Fite BioPharma (CANF) with a Buy rating and $2.50 price target The firm says the company has two late-stage oral selective A3 adenosine receptor agonists, that are being developed as therapies for psoriasis and liver cancer, respectively. It believes A3AR agonists are novel and can selectively target pathogenic cells.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma Reschedules Shareholder Meeting Due to Lack of Quorum
- Can-Fite BioPharma’s Phase 3 Psoriasis Study: A Potential Game Changer?
- Can-Fite BioPharma’s Promising Phase 3 Trial for Liver Cancer Treatment
- Can-Fite BioPharma’s Promising Phase 2 Study on Namodenoson for Pancreatic Cancer
- Can-Fite BioPharma Announces Special Shareholder Meeting for Capital Restructuring